Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas - PubMed (original) (raw)
Affiliations
- PMID: 16471323
Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas
G H Di et al. J Exp Clin Cancer Res. 2005 Dec.
Abstract
Estrogens can play a critical role in the development of breast cancer. Aromatase which catalyzes the formation of aromatic C18 estrogens from C19 androgens is regarded to be responsible for the cancer local production of estrogen. Studies not only from aromatase transfected breast cancer cells, but also transgenic mouse, which overexpressed aromatase, demonstrated that in situ produced estrogen plays more important roles than circulating estrogens in breast tumor promotion and progression. Matrix-metalloproteinases (MMPs) have been implicated in the proeolytic process, which play important roles in the aggressiveness of cancer cells including invasion of adjacent tissue and metastasis to distant sites. Expression of MMP2 and 9 may be stimulated by estrogens in hormonal dependent breast cancers, since tumor aromatase can stimulate breast cancer growth and progression in both an autocrine and a paracrine manner. Theoretically aromatase overexpression, that causes relatively high estrogen concentration in situ, may be positively related to MMP2 and 9 expression, indicate worse prognosis in breast cancers, and maybe insensitive to tamoxifen therapy. In the present study, we studied the expression of aromatase activity and MMPs in human breast carcinoma both in vitro and in vivo. In human breast carcinoma cell lines including MCF-7, MDA-MB-231 and MDA-MB-435, the expression of aromatase levels both in mRNA and protein activity was related to MMP2 and MMP9. In humam breast cancer samples, we demonstrated that aromatase expressions were strongly associated with MMP2 and MMP9 levels. It was interesting to observe that the positive relationship was only present in the ER and/or PR positive patients. This may indicate that both MMP2 and MMP9 were up regulated by estrogen produced by aromatase through ER. So in endocrine therapy, either blocking the ER by tamoxifen or inhibiting the aromatase by aromatase inhibitors for example letrozole, may both inhibit tumor growth and lower the metastatic potential especially in ER positive breast cancer patients by means of down-regulation of MMP2/9.
Similar articles
- [Clinicopathological significance of aromatase expression in breast cancers].
Lu JS, Li HC, Cao DC, Di GH, Wu J, Shen KW, Shen ZZ, Shao ZM. Lu JS, et al. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1318-21. Zhonghua Wai Ke Za Zhi. 2006. PMID: 17217816 Chinese. - The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M, Reed MJ, Al Sarakbi W, Jiang WG, Mokbel K. Salhab M, et al. Breast Cancer Res Treat. 2006 Sep;99(2):155-62. doi: 10.1007/s10549-006-9198-8. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541304 - An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT. Henriksen KL, et al. Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383. Acta Oncol. 2009. PMID: 19173092 - In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
Sasano H, Miki Y, Nagasaki S, Suzuki T. Sasano H, et al. Pathol Int. 2009 Nov;59(11):777-89. doi: 10.1111/j.1440-1827.2009.02444.x. Pathol Int. 2009. PMID: 19883428 Review. - [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
Rochefort H. Rochefort H. C R Seances Soc Biol Fil. 1998;192(2):241-51. C R Seances Soc Biol Fil. 1998. PMID: 9841098 Review. French.
Cited by
- Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer.
Biegon A, Shroyer KR, Franceschi D, Dhawan J, Tahmi M, Pareto D, Bonilla P, Airola K, Cohen J. Biegon A, et al. J Nucl Med. 2020 Jun;61(6):807-813. doi: 10.2967/jnumed.119.231589. Epub 2019 Nov 22. J Nucl Med. 2020. PMID: 31757843 Free PMC article. - Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.
Bocca C, Bozzo F, Bassignana A, Miglietta A. Bocca C, et al. Mol Cell Biochem. 2011 Apr;350(1-2):59-70. doi: 10.1007/s11010-010-0682-4. Epub 2010 Dec 8. Mol Cell Biochem. 2011. PMID: 21140284 - Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.
Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, Rodriguez JC, Lamelas ML, Vizoso FJ. Gonzalez LO, et al. BMC Cancer. 2008 May 28;8:149. doi: 10.1186/1471-2407-8-149. BMC Cancer. 2008. PMID: 18507821 Free PMC article. - Expression patterns and action analysis of genes associated with drug-induced liver diseases during rat liver regeneration.
Ning QJ, Qin SW, Xu CS. Ning QJ, et al. World J Gastroenterol. 2006 Nov 21;12(43):6966-72. doi: 10.3748/wjg.v12.i43.6966. World J Gastroenterol. 2006. PMID: 17109518 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous